Earnings ESP

Search documents
Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?
ZACKS· 2025-07-28 15:31
Industry Overview - The second-quarter 2025 reporting cycle for the Medical sector is commencing, with most firms expected to release earnings results in the next two weeks, primarily consisting of pharma/biotech and medical device companies [1] - The earnings season for the drug and biotech sector began in mid-July, highlighted by Johnson & Johnson's strong performance, which exceeded earnings and sales estimates, leading to raised revenue and earnings expectations for the year [1] Company Performance - Novartis surpassed second-quarter earnings and revenue estimates, driven by a year-over-year increase in sales of key drugs, prompting an upward revision of its annual guidance for core operating income [2] - Roche experienced solid growth in the first half of 2025, with high demand for key drugs offsetting declines in legacy drug sales [2] - As of July 23, 15% of companies in the Medical sector, representing 27.2% of the sector's market capitalization, reported quarterly earnings, with 88.9% outperforming earnings estimates and 100% beating revenue estimates [3] - Overall, second-quarter earnings for the Medical sector are projected to increase by 0.9%, while sales are expected to rise by 7.9% compared to the previous year [3] Upcoming Earnings Reports - Merck, AstraZeneca, Bristol Myers, AbbVie, and Moderna are scheduled to release their quarterly results this week [4] - Merck has a strong earnings track record, beating estimates in the last four quarters with an average surprise of 3.82% [5] - AstraZeneca has a mixed earnings history, beating estimates in three of the last four quarters, with an average surprise of 4.24% [8] - Bristol Myers has consistently beaten earnings estimates, with an average surprise of 20.16% over the last four quarters [11] - AbbVie has also maintained a strong track record, beating estimates in the last four quarters with an average surprise of 2.55% [13] - Moderna has an excellent earnings history, with an average surprise of 31.60% in the last four quarters [15] Sales Drivers - Merck's growth in the second quarter is likely attributed to increased sales of its cancer drug Keytruda, driven by additional indications and patient demand [7] - AstraZeneca's sales are expected to be bolstered by strong demand for its cancer and diabetes medications [10] - Bristol Myers' revenue may be impacted by declines in legacy drug sales, but growth products are expected to partially offset this decline [12] - AbbVie's revenue is anticipated to be driven by strong sales of key drugs and contributions from newer products [14] - Moderna's revenues are expected to be influenced by sales of its COVID-19 vaccine, Spikevax, while the focus is shifting to updates on its broader pipeline [16]
What's in the Cards for Arthur J. Gallagher This Earnings Season?
ZACKS· 2025-07-28 15:11
Core Insights - Arthur J. Gallagher & Co. (AJG) is anticipated to show improvements in both revenue and earnings for Q2 2025, with revenue expected to reach $3.17 billion, reflecting a 15.8% year-over-year growth [1] - The earnings consensus estimate is $2.36 per share, indicating a 4.4% increase from the previous year, although this estimate has decreased by 0.8% in the last 30 days [2] Financial Performance Expectations - The Zacks Consensus Estimate for fees is projected at $925 million, representing a 12% increase from the prior year, while commissions are expected to reach $1.8 billion, indicating a 12.5% growth [6] - Factors contributing to the expected performance include strong client retention, new business generation, and higher renewal premiums across AJG's business lines [5][7] Earnings Prediction Model - The current model does not predict an earnings beat for AJG, as it has an Earnings ESP of -0.05% and a Zacks Rank of 4 (Sell) [3][4] Segment Performance - The Risk Management segment is expected to benefit from excellent client retention and increased customer business activity [6] - The Brokerage segment is likely to see improvements due to higher new business generation and increased interest income [7] Expense Outlook - Total expenses are anticipated to rise primarily due to increased compensation, reimbursements, and changes in estimated acquisition earnout payables [8]
Carpenter Technology Ready to Report Q4 Earnings: What's in Store?
ZACKS· 2025-07-28 15:11
Core Insights - Carpenter Technology Corporation (CRS) is set to report its fourth-quarter fiscal 2025 results on July 31, with sales estimated at $770 million, reflecting a 3.6% decrease from the previous year [1] - The earnings consensus estimate for CRS is $2.03 per share, indicating an 11.5% year-over-year growth, with a 0.5% increase in the estimate over the past 60 days [1][4] - CRS has a strong earnings surprise history, beating estimates in the last four quarters with an average surprise of 11.1% [3][4] Financial Performance Expectations - The Specialty Alloys Operations segment is expected to report sales of $689 million, down 3.7% year-over-year, with an operating profit projected at $163 million, up from $141 million in the same quarter last year [9] - Performance Engineered Products' net sales are anticipated to rise 1.5% year-over-year to $113 million, with an operating profit expected to increase to $11.7 million from $10.6 million [10] Market Dynamics - Demand in aerospace, defense, and medical applications is expected to support CRS's performance, despite challenges from labor and chip shortages [7][8] - Increased productivity, higher prices, and an improved product mix are likely to have positively impacted margins, countering the effects of soft sales volume [8] Stock Performance - CRS shares have increased by 97.4% over the past year, significantly outperforming the industry growth of 46.7% [11]
BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth
ZACKS· 2025-07-28 15:06
Wall Street expects a year-over-year increase in earnings on higher revenues when BioMarin Pharmaceutical (BMRN) reports results for the quarter ended June 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on August 4, might help the stock move higher if these key numbers are better than ...
Earnings Preview: Crescent Energy (CRGY) Q2 Earnings Expected to Decline
ZACKS· 2025-07-28 15:06
Core Viewpoint - Crescent Energy (CRGY) is expected to report a year-over-year decline in earnings despite higher revenues, with the actual results being crucial for stock price movement [1][2]. Earnings Expectations - The upcoming earnings report is anticipated on August 4, with expected earnings of $0.23 per share, reflecting a year-over-year decrease of 25.8% [3]. - Revenues are projected to be $895.46 million, which is an increase of 37.1% compared to the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 17.02% higher in the last 30 days, indicating a reassessment by analysts [4]. - Crescent Energy's Most Accurate Estimate aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0% [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likelihood of actual earnings deviating from consensus estimates, with a positive reading being a strong predictor of an earnings beat [9][10]. - Crescent Energy currently holds a Zacks Rank of 1, but the combination with a 0% Earnings ESP makes it challenging to predict an earnings beat [12]. Historical Performance - In the last reported quarter, Crescent Energy exceeded the expected earnings of $0.47 per share by delivering $0.56, resulting in a surprise of +19.15% [13]. - The company has beaten consensus EPS estimates in all of the last four quarters [14]. Market Reaction Factors - An earnings beat or miss may not solely dictate stock movement, as other factors can influence investor sentiment [15]. - Despite not appearing as a compelling earnings-beat candidate, other market conditions should be considered when evaluating Crescent Energy [17].
BellRing Brands (BRBR) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
ZACKS· 2025-07-28 15:06
Company Overview - BellRing Brands (BRBR) is anticipated to report a year-over-year decline in earnings of 9.3%, with expected earnings per share (EPS) of $0.49 for the quarter ended June 2025 [3][12] - Revenue is projected to be $531.85 million, reflecting a 3.2% increase from the previous year [3] Earnings Expectations - The upcoming earnings report is scheduled for August 4, and the stock may experience upward movement if key numbers exceed expectations [2] - Conversely, if the results fall short, the stock may decline [2] Estimate Revisions - The consensus EPS estimate has been revised 0.02% higher in the last 30 days, indicating a slight positive adjustment by analysts [4] - The Most Accurate Estimate for BellRing Brands is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +2.06%, suggesting a bullish outlook from analysts [12] Earnings Surprise History - In the last reported quarter, BellRing Brands met the expected EPS of $0.53, resulting in no surprise [13] - Over the past four quarters, the company has beaten consensus EPS estimates three times [14] Industry Context - Chefs' Warehouse (CHEF), another player in the Zacks Food - Miscellaneous industry, is expected to report an EPS of $0.45, indicating a year-over-year increase of 12.5% [18] - Chefs' Warehouse's revenue is projected to be $1.02 billion, up 6.8% from the previous year [18]
CRISPR Therapeutics AG (CRSP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
ZACKS· 2025-07-28 15:06
Company Overview - CRISPR Therapeutics AG (CRSP) is expected to report a quarterly loss of $1.47 per share, reflecting a year-over-year change of +1.3% [3] - Revenues are anticipated to be $6.58 million, representing a significant increase of 1165.4% from the same quarter last year [3] Earnings Estimates and Revisions - The consensus EPS estimate has been revised 1.75% lower over the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for CRISPR Therapeutics is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -11.09% [12] Earnings Surprise Prediction - A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a favorable Zacks Rank [10] - CRISPR Therapeutics currently holds a Zacks Rank of 4, which complicates the prediction of an earnings beat [12] Historical Performance - In the last reported quarter, CRISPR Therapeutics was expected to post a loss of $1.27 per share but actually reported a loss of -$1.58, resulting in a surprise of -24.41% [13] - Over the past four quarters, the company has beaten consensus EPS estimates two times [14] Industry Context - Another player in the biomedical and genetics industry, Illumina (ILMN), is expected to post earnings of $1.02 per share, indicating a year-over-year change of +183.3% [18] - Illumina's revenues are projected to be $1.05 billion, down 5.8% from the previous year, with a slight downward revision of 0.2% in the consensus EPS estimate over the last 30 days [19]
Freshpet (FRPT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
ZACKS· 2025-07-28 15:06
Company Overview - Freshpet (FRPT) is expected to report a year-over-year increase in earnings, with a consensus estimate of $0.12 per share, reflecting a +500% change, and revenues projected at $267.74 million, up 13.8% from the previous year [3]. Earnings Expectations - The earnings report is anticipated to be released on August 4, and the stock may rise if the results exceed expectations, while a miss could lead to a decline [2]. - The consensus EPS estimate has been revised 1.32% lower over the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - Freshpet has an Earnings ESP of +40.68%, suggesting analysts have recently become more optimistic about the company's earnings prospects [12]. - However, the stock currently holds a Zacks Rank of 5, complicating the prediction of an earnings beat [12]. Historical Performance - In the last reported quarter, Freshpet was expected to earn $0.13 per share but only achieved $0.09, resulting in a surprise of -30.77% [13]. - Over the past four quarters, the company has beaten consensus EPS estimates twice [14]. Industry Comparison - Ingredion (INGR), another player in the Zacks Food - Miscellaneous industry, is expected to post earnings of $2.78 per share, indicating a year-over-year change of -3.1%, with revenues projected at $1.9 billion, up 1.3% [18][19]. - Ingredion's consensus EPS estimate has been revised 2% upward in the last 30 days, but it has an Earnings ESP of 0% and a Zacks Rank of 2 [19][20].
Hagerty, Inc. (HGTY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
ZACKS· 2025-07-28 15:06
Core Viewpoint - Hagerty, Inc. (HGTY) is anticipated to report a year-over-year increase in earnings and revenues for the quarter ended June 2025, with the actual results having a significant impact on the stock price [1][2]. Earnings Expectations - The consensus estimate for Hagerty's quarterly earnings is $0.13 per share, reflecting an 8.3% increase year-over-year, while revenues are expected to reach $354.53 million, up 13.2% from the previous year [3]. - The consensus EPS estimate has been revised 6.45% higher in the last 30 days, indicating a positive reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model shows a positive Earnings ESP of +42.10% for Hagerty, suggesting analysts are optimistic about the company's earnings prospects [12]. - The stock holds a Zacks Rank of 1, indicating a strong likelihood of beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, Hagerty exceeded the expected earnings of $0.02 per share by delivering $0.08, resulting in a surprise of +300.00% [13]. - Over the past four quarters, the company has beaten consensus EPS estimates three times [14]. Conclusion - Hagerty is positioned as a compelling candidate for an earnings beat, but investors should consider additional factors beyond earnings expectations when making investment decisions [17].
Ichor Holdings (ICHR) Reports Next Week: Wall Street Expects Earnings Growth
ZACKS· 2025-07-28 15:06
Core Viewpoint - Ichor Holdings (ICHR) is anticipated to report a year-over-year increase in earnings and revenues for the quarter ended June 2025, with earnings expected to be $0.14 per share, reflecting a 180% increase, and revenues projected at $235.48 million, up 15.9% from the previous year [1][3]. Earnings Expectations - The upcoming earnings report is scheduled for August 4, and the stock may rise if the reported numbers exceed expectations, while a miss could lead to a decline [2]. - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model shows a positive Earnings ESP of +12.28% for Ichor Holdings, suggesting analysts have recently become more optimistic about the company's earnings prospects [12]. - A positive Earnings ESP is a strong indicator of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [10]. Historical Performance - In the last reported quarter, Ichor Holdings had an expected EPS of $0.26 but reported only $0.12, resulting in a surprise of -53.85% [13]. - Over the past four quarters, the company has beaten consensus EPS estimates two times [14]. Industry Context - Qualcomm (QCOM), a peer in the electronics-semiconductors industry, is expected to report earnings of $2.68 per share, reflecting a 15% year-over-year increase, with revenues projected at $10.36 billion, up 10.3% from the previous year [18]. - Qualcomm's consensus EPS estimate has been revised up by 0.3% over the last 30 days, and it has an Earnings ESP of +0.6%, indicating a likelihood of beating the consensus EPS estimate [19].